Market Overview

Applied DNA, TheraCann International to Introduce Cannabis Tagging System (CTS) at the NCIA Cannabis Business Summit & Expo July 25-27

Share:

Debut of patent-pending device for production tagging by growers of
mature plants

Applied
DNA Sciences, Inc.
, (NASDAQ:APDN), the leader in DNA-based
authentication, in conjunction with TheraCann International (TheraCann)
will launch the cannabis industry's first cannabis tagging system (CTS)
using Applied DNA's CertainT® platform of tag, test and track. The
device
is designed to rapidly molecularly tag cannabis plants in
commercial harvests of any scale. Once the molecular tag is applied, the
plants and their derivative products can be forensically tracked through
every stage of the supply chain all the way to the consumer.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180724005055/en/

The integrated solution being offered by Applied DNA and TheraCann,
called ETCH Biotrace, is uniquely positioned at a very critical time in
the maturation of the cannabis industry. Legal cannabis markets for
medicinal and recreational use have enjoyed rapid development globally,
paced by Uruguay,
Canada, the Netherlands and Australia
, all of which have legalized
the export of medical cannabis. More recently, in North America, Canada
is set to legalize recreational cannabis in October 2018, joining
9 U.S. states
and Washington D.C., and 29 additional US states that
have legalized cannabis for medicinal use.

Gordon Hope, Director of Cannabis Business Development of Applied DNA,
said, "Combining our mature tagging expertise with the new seed-to-sale
solution by TheraCann enhanced with ETCH Biotrace, provides for the
first time, true transparency across the entire cannabis supply chain,
from cultivator to processor and dispensary."

The CTS is designed to tag plants directly during harvest. All the data
associated with the tagging process will flow through Applied DNA's and
TheraCann's integrated platform and will be presented to the appropriate
stakeholders through dashboards and detailed reporting. Early testing
has shown that Applied DNA's tag will survive processing and can also be
detected in cannabis derivative products such as cannabis oils, Rick
Simpson oil, budder, and shatter.

Dr. James Hayward, president and CEO of Applied DNA, said, "As adoption
of legal cannabis legislation gains momentum globally, having the
capability to track cannabis supply chains from seed-to-sale can assure
stakeholders of compliance with regulatory and legal requirements. By
tagging the physical plant, we enable cultivators, processors and
dispensaries to proactively authenticate their products throughout the
supply chain and share that transparency with consumers and state
governments."

The US legal cannabis market reached $7 billion by 2016 and is expected
to top $50 billion within the next 10 years. Tax benefits to individual
states can be significant (over $200 million in Colorado in 2017), but
the industry remains a challenge for regulators. (Prohibition Partners,
The European Cannabis Report, First Edition, April 2017).

"The global cannabis market is growing at remarkable speed and the
commercial ecosystem is becoming increasingly complex. A robust platform
like the one we are introducing is required to provide a true end-to-end
solution that addresses an ever-expanding global market," stated Jason
Warnock, CEO of TheraCann International.

About TheraCann International Benchmark Corporation

Founded in 2004, TheraCann International Benchmark Corporation offers a
one-stop, full-service solution for the International cannabis
marketplace. TheraCann provides business, technology and industry
experts who apply advanced technology to help clients design, build and
run their cannabis businesses. With nearly 3.5 million square feet of
cannabis operations under management and the successful launch of
groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic
cultivation systems and patented genetic tracking and diversion
prevention systems, TheraCann provides cannabis-related businesses with
solutions to fit their regulatory requirements. More information about
TheraCann is available at www.theracanncorp.com.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply
chain security, anti-counterfeiting and anti-theft technology, product
genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
and diversion. The proprietary DNA-molecular based "CertainT®"
platform can be used to identify, tag, test, and track products, to help
assure authenticity, origin, traceability, sustainability and quality of
products. SigNature® DNA describes the core technology
ingredient that is at the heart of a family of uncopyable, security and
authentication solutions such as SigNature® T and fiberTyping®,
targeted toward textiles and apparel, BackTrac™ and DNAnet®,
for anti-theft and loss prevention, and digitalDNA®,
providing powerful track-and-trace. All provide a forensic chain of
evidence, and can be used to prosecute perpetrators. Applied DNA
Sciences is also engaged in the large-scale production of specific DNA
sequences using the polymerase chain reaction.

Visit adnas.com for
more information. Follow us on Twitter and LinkedIn.
Join our mailing
list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are
listed under the symbol APDNW.

Forward Looking Statements

The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe Applied
DNA's future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties,
many of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to our history of
losses, limited financial resources, limited market acceptance, shifting
enforcement priorities of US federal laws relating to cannabis, and
various other factors detailed from time to time in Applied DNA's SEC
reports and filings, including our Annual Report on Form 10-K filed on
December 28, 2017 and our subsequent quarterly reports on Form 10-Q
filed on February 8, 2018 and May 3, 2018, which are available at www.sec.gov.
APDN undertakes no obligation to update publicly
any forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.

View Comments and Join the Discussion!